Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

NCT05844423 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

802

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Vaccines

Interventions

BIOLOGICAL: 0.5 ml dose of 1.1 mcg VAX-24
BIOLOGICAL: 0.5 ml dose of PCV20
BIOLOGICAL: 0.5 ml dose of 2.2 mcg VAX-24
BIOLOGICAL: 0.5 ml dose of 2.2/4.4 mcg VAX-24

Sponsor

Vaxcyte, Inc.